Lite Strategy (LITS) Assets Average (2011 - 2026)
Lite Strategy (LITS) posted quarterly Assets Average of $70.4 million for Q1 2026, up 211.59% year-over-year from $22.6 million in Q1 2025, and down 28.3% quarter-over-quarter from $98.1 million in Q4 2025.
Lite Strategy (LITS) Assets Average (2011 - 2026) Analysis & Trends
Lite Strategy's Assets Average history runs 16 years deep, the most recent figure standing at $70.4 million for Q1 2026.
- In Q1 2026, Assets Average rose 211.59% year-over-year to $70.4 million; the TTM figure through Mar 2026 stood at $70.4 million (up 211.59% YoY), while the FY2025 annual figure was $29.8 million, down 63.21% from the prior year.
- Assets Average for Q1 2026 stood at $70.4 million, down from $98.1 million in the prior quarter.
- The five-year high for Assets Average was $201.9 million in Q1 2022, with the low at $19.5 million in Q2 2025.
- The 5-year median for Assets Average is $89.9 million (2023), against an average of $97.2 million.
- The sharpest annual moves came in 2024 and 2025: Assets Average plunged 71.0% in 2024, then jumped 276.47% in 2025.
- Lite Strategy's Assets Average stood at $155.6 million in 2022, then plunged by 42.22% to $89.9 million in 2023, then slumped by 71.0% to $26.1 million in 2024, then surged by 276.47% to $98.1 million in 2025, then slipped by 28.3% to $70.4 million in 2026.
- Business Quant data shows LITS's Assets Average at $70.4 million in Q1 2026, $98.1 million in Q4 2025, and $65.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Lite Strategy | 33.69 Mn | 26.14 Mn | - | 70.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.36 Mn |
| Dec 31, 2025 | 98.14 Mn |
| Sep 30, 2025 | 65.81 Mn |
| Jun 30, 2025 | 19.53 Mn |
| Mar 31, 2025 | 22.58 Mn |
| Dec 31, 2024 | 26.07 Mn |
| Sep 30, 2024 | 34.56 Mn |
| Jun 30, 2024 | 56.32 Mn |
| Mar 31, 2024 | 74.90 Mn |
| Dec 31, 2023 | 89.89 Mn |
| Sep 30, 2023 | 111.03 Mn |
| Jun 30, 2023 | 127.50 Mn |
| Mar 31, 2023 | 140.89 Mn |
| Dec 31, 2022 | 155.59 Mn |
| Sep 30, 2022 | 170.71 Mn |
| Jun 30, 2022 | 186.13 Mn |
| Mar 31, 2022 | 201.95 Mn |
| Dec 31, 2021 | 192.91 Mn |
| Sep 30, 2021 | 175.22 Mn |
| Jun 30, 2021 | 180.11 Mn |